Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | MMP1 | P03956 | 4/20 | 0.53 |
| ▸ | MMP8 | P22894 | 4/20 | 0.53 |
| ▸ | MMP13 | P45452 | 4/20 | 0.53 |
| ▸ | MMP7 | P09237 | 3/20 | 0.53 |
| ▸ | MMP12 | P39900 | 3/20 | 0.53 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.45 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.45 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2414975 | 0.81 | SIGMAR1 (0.57) | SMN1; SMN2MEN1KMT2APLCG1RAB9A | |
| SCHEMBL9185463 | 0.81 | SMN1; SMN2 (0.46) | SMN1; SMN2GAANPC1MMP1MMP8 | |
| SCHEMBL2932532 | 0.81 | CA9 (0.62) | SMN1; SMN2NPC1VCAM1MEN1HTT | |
| SCHEMBL6676536 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2GAANPC1MMP1MMP8 | |
| SCHEMBL6257441 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2GAANPC1MMP1MMP8 | |
| SCHEMBL218536 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2GAANPC1MMP1MMP8 | |
| SCHEMBL8157313 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2GAANPC1MMP1MMP8 | |
| SCHEMBL3622125 | 0.80 | SMN1; SMN2 (0.67) | SMN1; SMN2GAANPC1MMP1MMP8 | |
| SCHEMBL15177296 | 0.79 | SMN1; SMN2 (0.66) | SMN1; SMN2GAANPC1MMP1MMP8 | |
| SCHEMBL8192690 | 0.79 | SMN1; SMN2 (0.66) | SMN1; SMN2GAANPC1MMP1MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3149109-B1 | POLYMERISABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | MERCK PATENT GMBH (DE) | 2019-10-16 | — | — | EP | disclosed |
| WO-2015180819-A1 | POLYMERISABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | MERCK PATENT GMBH (DE) | 2015-12-03 | — | — | WO | disclosed |
| US-20100216790-A1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2010-08-26 | — | — | US | disclosed |
| US-7709488-B2 | Imidazopyridine-derivatives as inducible no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2010-05-04 | — | — | US | disclosed |
| EP-1670796-B1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | NYCOMED GMBH (DE) | 2008-06-25 | — | — | EP | disclosed |
| US-20080021039-A1 | Imidazopyridine-derivatives as inducible no-synthase inhibitors | ALTANA PHARMA AG | 2008-01-24 | — | — | US | disclosed |
| US-7279488-B2 | Imidazopyridine-derivatives as inducible no-synthase inhibitors | NYCOMED GMBH (DE) | 2007-10-09 | — | — | US | disclosed |
| US-20060293302-A1 | Imidazopyridine-derivatives as inducible no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2006-12-28 | — | — | US | disclosed |
| EP-1670796-A1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | ALTANA Pharma AG (DE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005030770-A1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293302-A1 | Imidazopyridine-derivatives as inducible no-synthase inhibitors | NOS2, NOS1, NOS3 | SMN1; SMN2 4215/4885GAA 3086/4885NPC1 3800/4885 |
| US-20080021039-A1 | Imidazopyridine-derivatives as inducible no-synthase inhibitors | NOS2, NOS1, NOS3 | SMN1; SMN2 4215/4885GAA 3086/4885NPC1 3800/4885 |
| US-20100216790-A1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | NOS2, NOS1, NOS3 | SMN1; SMN2 4215/4885GAA 3086/4885NPC1 3800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.